Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1471

Shown on this page

Current sort

Live official records

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: FG-3246; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Radiation Exposure
Interventions: Standard PPE, Texray PPE; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 594
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more

Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 76
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more

Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions: Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2036
U.S. locations: 106
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more

Conditions: Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer
Interventions: SIM0505 for injection; Drug
Lead sponsor: NextCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 6 more

Conditions: Ulcerative Colitis
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more

Conditions: Breast Carcinoma
Interventions: Best Practice, Discussion, Interview - Stakeholder, Interview - Key Informant, Interview - Ancillary studies, Patient Navigation - C Components, Patient Navigation - B components, Patient Navigation - A components, Survey Administration, Survey Administration - Ancillary studies; Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced Solid Neoplasms
Interventions: Olaparib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 24
States / cities: Tucson, Arizona • Fullerton, California • Los Angeles, California + 17 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
Interventions: Orca-T; Biological
Lead sponsor: Orca Biosystems, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Stroke Hemorrhagic
Interventions: Surgical management, Medical Management; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Carfilzomib, Maplirpacept; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 31
States / cities: Little Rock, Arkansas • Beverly Hills, California • Encino, California + 15 more

About this Emory University (Winship Cancer Institute) institution page

What this page lists: ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Emory University (Winship Cancer Institute)

Filter and sort this campus

Live official records

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Evaluation of a Novel Textile Radiation Protection Device

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

About this Emory University (Winship Cancer Institute) institution page